Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy

philhyu Lee, J. W. Kim, O. Y. Bang, Y. H. Ahn, I. S. Joo, K. Huh

Research output: Contribution to journalArticle

162 Citations (Scopus)

Abstract

We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.

Original languageEnglish
Pages (from-to)723-730
Number of pages8
JournalClinical Pharmacology and Therapeutics
Volume83
Issue number5
DOIs
Publication statusPublished - 2008 May 30

Fingerprint

Multiple System Atrophy
Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Cerebellar Diseases
Dizziness
Intravenous Injections
Positron-Emission Tomography
Cerebellum
Safety
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{3500407340d14492bd6809de8e6b228b,
title = "Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy",
abstract = "We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.",
author = "philhyu Lee and Kim, {J. W.} and Bang, {O. Y.} and Ahn, {Y. H.} and Joo, {I. S.} and K. Huh",
year = "2008",
month = "5",
day = "30",
doi = "10.1038/sj.clpt.6100386",
language = "English",
volume = "83",
pages = "723--730",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "5",

}

Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. / Lee, philhyu; Kim, J. W.; Bang, O. Y.; Ahn, Y. H.; Joo, I. S.; Huh, K.

In: Clinical Pharmacology and Therapeutics, Vol. 83, No. 5, 30.05.2008, p. 723-730.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy

AU - Lee, philhyu

AU - Kim, J. W.

AU - Bang, O. Y.

AU - Ahn, Y. H.

AU - Joo, I. S.

AU - Huh, K.

PY - 2008/5/30

Y1 - 2008/5/30

N2 - We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.

AB - We evaluated the feasibility and safety of therapy with mesenchymal stem cells (MSCs) through consecutively intra-arterial and three repeated intravenous injections and compared the long-term prognosis between MSC-treated (n=11) and control multiple system atrophy (MSA) patients (n=18). The MSC-treated patients showed significantly greater improvement on the unified MSA rating scale (UMSARS) than the control patients at all visits throughout the 12-month study period. Orthostasis in UMSARS I items and cerebellar dysfunction-related items of UMSARS II items were significantly different in favor of MSC treatment compared to controls. Serial positron emission tomography scan in the MSC-treated group showed that increased fluorodeoxyglucose uptake from baseline was noted in cerebellum and frontal white matters. No serious adverse effects related to MSC therapy occurred. This study demonstrated that MSC therapy in patients with MSA was safe and delayed the progression of neurological deficits with achievement of functional improvement in the follow-up period.

UR - http://www.scopus.com/inward/record.url?scp=42349097728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349097728&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100386

DO - 10.1038/sj.clpt.6100386

M3 - Article

VL - 83

SP - 723

EP - 730

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 5

ER -